论文部分内容阅读
目的探讨格列美脲联合二甲双胍治疗2型糖尿病的疗效和安全性。方法选取136例患者1:1随机分为两组,对照组采用二甲双胍治疗,观察组采用格列美脲联合二甲双胍治疗,比较两组疗效和安全性。结果治疗后,两组患者FBG、2hPBG、HbA1c均明显降低,与治疗前差异有统计学意义(P<0.05),且观察组下降更为明显,与对照组相比差异有统计学意义(P<0.05);BMI治疗前、后两组差异均无统计学意义(P>0.05);观察组低血糖不良反应发生率5.88%,胃肠反应发生率7.35%,对照组分别为4.41%和5.88%,观察组高于对照组,但并无统计学意义(P>0.05)。结论格列美脲联合二甲双胍治疗2型糖尿病,对FBG、2hPBG、HbA1c控制明显,且未增加不良反应的发生,是一种安全有效的治疗方法。
Objective To investigate the efficacy and safety of glimepiride combined with metformin in the treatment of type 2 diabetes mellitus. Methods One hundred and sixty-six patients were randomly divided into two groups. The control group was treated with metformin. The observation group was treated with glimepiride and metformin. The curative effect and safety of the two groups were compared. Results After treatment, FBG, 2hPBG and HbA1c in both groups were significantly lower than those before treatment (P <0.05), and the decrease in the observation group was more obvious (P <0.05). There was no significant difference between the two groups before and after BMI treatment (P> 0.05). The incidence of hypoglycemic adverse reactions in the observation group was 5.88% and the incidence of gastrointestinal reactions was 7.35% in the observation group and 4.41% and 5.88% in the control group %, The observation group than the control group, but no statistical significance (P> 0.05). Conclusion Glibenclamide and metformin are effective and safe for treatment of type 2 diabetes with obvious control of FBG, 2hPBG and HbA1c without increasing the occurrence of adverse reactions.